67 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Limited
5 Sep 24
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
4:20pm
- net
Net (loss) / income before income tax
Income tax expense
Net (loss) / income attributable to:
Owners of the Company
Net (loss) / income per share
6-K
CNTB
Connect Biopharma Holdings Limited
5 Sep 24
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
4:20pm
Finance income - net
Net (loss) / income before income tax
Income tax expense
Net (loss) / income
Net (loss) / income attributable to:
Owners … comprehensive income
Other comprehensive loss, net of tax
Total comprehensive (loss) / income
Total comprehensive (loss) / income attributable
6-K
EX-10.2
CNTB
Connect Biopharma Holdings Limited
12 Jun 24
Current report (foreign)
4:47pm
and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax imposed by Section 4999 of the Code.
(f … , under or in concert with Executive will disclose to any individual or entity (other than Executive’s spouse, legal or tax advisors) the terms
6-K
EX-10.3
CNTB
Connect Biopharma Holdings Limited
12 Jun 24
Current report (foreign)
4:47pm
by Executive as a result of the payments and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax … Executive’s spouse, legal or tax advisors) the terms of this Agreement.
(e)Rights and Remedies Upon Breach. If Executive breaches or threatens
6-K
EX-10.1
CNTB
Connect Biopharma Holdings Limited
12 Jun 24
Current report (foreign)
4:47pm
to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation with respect to an Award … (including Shares retained
by the Company from the Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again
6-K
EX-99.1
kwo8t82b6oj8q9
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
6-K
EX-99.1
jmd0u3qot5t7xm6zdq4
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.1
y25626dw8phnswy
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
mzf36wi 45fwbxq
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
6mm1tu
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
EX-99.1
x08gysh6b
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
44w0m7
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
wlp0yzijnpx16cmgob1e
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
b0trh8vk
20 May 22
Shelf registration (foreign) (amended)
6:54pm
F-3
lmkmpbjluyziaqyb
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
EX-5.1
8vrkf9huysfcz
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
EX-1.2
99h v5b40bk
15 Apr 22
Shelf registration (foreign)
5:27pm